Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gynecology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 77 articles: HTML format

Single Articles

July 2021
1. XU XM, Wang XB, Chen MM, Liu T, et al
   Retraction notice to "MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5" [Canc. Lett. 322 (2012) 148-158].
   Cancer Lett. 2021 Jul 14. pii: S0304-3835(21)00330.
   PubMed     Abstract available
   
   
   
2. CHEN C, Shen N, Chen Y, Jiang P, et al
   LncCCLM inhibits lymphatic metastasis of cervical cancer by promoting STAU1-mediated IGF-1 mRNA degradation.
   Cancer Lett. 2021;518:169-179.
   PubMed     Abstract available
   
   
   June 2021
3. WANG D, He J, Dong J, Wu S, et al
   UM-6 induces autophagy and apoptosis via the Hippo-YAP signaling pathway in cervical cancer.
   Cancer Lett. 2021 Jun 20. pii: S0304-3835(21)00244.
   PubMed     Abstract available
   
   
   May 2021
4. YANG B, Chen J, Li X, Zhang X, et al
   TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer.
   Cancer Lett. 2021 May 24. pii: S0304-3835(21)00240.
   PubMed     Abstract available
   
   
   
5. DAI M, Yang B, Chen J, Liu F, et al
   Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer.
   Cancer Lett. 2021 May 12. pii: S0304-3835(21)00190.
   PubMed     Abstract available
   
   
   March 2021
6. QIN X, Zhou M, Lv H, Mao X, et al
   Corrigendum to "Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3" [Canc. Lett. 498 (2021) 130-141].
   Cancer Lett. 2021;508:73-75.
   PubMed    
   
   
   
7. XANTHOULEA S, Konings GF, Saarinen N, Delvoux B, et al
   Pharmacological inhibition of 17beta-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model.
   Cancer Lett. 2021 Mar 21. pii: S0304-3835(21)00124.
   PubMed     Abstract available
   
   
   
8. WAN HY, Li QQ, Zhang Y, Tian W, et al
   Corrigendum to "MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells" [Cancer Letters 355 (2014) 148-158].
   Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00087.
   PubMed    
   
   
   February 2021
9. KURNIT KC, Draisey A, Kazen RC, Chung C, et al
   Loss of CD73 shifts transforming growth factor-beta1 (TGF-beta1) from tumor suppressor to promoter in endometrial cancer.
   Cancer Lett. 2021 Feb 17. pii: S0304-3835(21)00062.
   PubMed     Abstract available
   
   
   
10. LUO Q, Wu X, Zhang Y, Shu T, et al
    Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Cancer Lett. 2021;498:243.
    PubMed    
    
    
    January 2021
11. LIU Y, Yang J, Shi Z, Tan X, et al
    In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
    Cancer Lett. 2021 Jan 29. pii: S0304-3835(21)00048.
    PubMed     Abstract available
    
    
    
12. BHARDWAJ V, Tan YQ, Wu MM, Ma L, et al
    Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Cancer Lett. 2021 Jan 8. pii: S0304-3835(21)00010.
    PubMed     Abstract available
    
    
    December 2020
13. BUNGSY M, Palmer MCL, Jeusset LM, Neudorf NM, et al
    Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Cancer Lett. 2020 Dec 5. pii: S0304-3835(20)30649.
    PubMed     Abstract available
    
    
    November 2020
14. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Cancer Lett. 2020 Nov 19. pii: S0304-3835(20)30603.
    PubMed     Abstract available
    
    
    October 2020
15. QIN X, Zhou M, Lv H, Mao X, et al
    Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3.
    Cancer Lett. 2020 Oct 28. pii: S0304-3835(20)30578.
    PubMed     Abstract available
    
    
    
16. YUAN Y, Cai X, Shen F, Ma F, et al
    HPV post-infection microenvironment and cervical cancer.
    Cancer Lett. 2020 Oct 26. pii: S0304-3835(20)30568.
    PubMed     Abstract available
    
    
    
17. REVATHIDEVI S, Murugan AK, Nakaoka H, Inoue I, et al
    APOBEC: A molecular driver in cervical cancer pathogenesis.
    Cancer Lett. 2020 Oct 7. pii: S0304-3835(20)30503.
    PubMed     Abstract available
    
    
    September 2020
18. KOK-TING WAN P, Ho-Yin Leung T, Kwan-Yee Siu M, Mo X, et al
    HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer.
    Cancer Lett. 2020 Sep 30. pii: S0304-3835(20)30495.
    PubMed     Abstract available
    
    
    
19. XIE Z, Wang F, Lin L, Duan S, et al
    An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30467.
    PubMed     Abstract available
    
    
    August 2020
20. TOCCI P, Cianfrocca R, Sestito R, Rosano L, et al
    Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30439.
    PubMed     Abstract available
    
    
    
21. HU H, Chen Z, Ji L, Wang Y, et al
    ARID1A-dependent permissive chromatin accessibility licenses estrogen-receptor signaling to regulate circadian rhythms genes in endometrial cancer.
    Cancer Lett. 2020 Aug 25. pii: S0304-3835(20)30448.
    PubMed     Abstract available
    
    
    
22. SUN Y, Yang X, Liu M, Tang H, et al
    Corrigendum to "B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells." [Canc. Lett. 375 (2016) 284-292].
    Cancer Lett. 2020;493:16-18.
    PubMed    
    
    
    June 2020
23. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available
    
    
    March 2020
24. XU Y, Li Y, Pan J, Kang X, et al
    EM2D9, a monoclonal antibody against Integrin a5b1, has potent antitumor activity on endometrial cancer in vitro and in vivo.
    Cancer Lett. 2020 Mar 3. pii: S0304-3835(20)30082.
    PubMed     Abstract available
    
    
    February 2020
25. SHENG R, Li X, Wang Z, Wang X, et al
    Response to Comments on Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Feb 20. pii: S0304-3835(20)30068.
    PubMed    
    
    
    
26. BERGSTEN TM, Burdette JE, Dean M
    Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.
    Cancer Lett. 2020 Feb 14. pii: S0304-3835(20)30080.
    PubMed     Abstract available
    
    
    
27. GU C, Yang H, Chang K, Zhang B, et al
    Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation.
    Cancer Lett. 2020;476:34-47.
    PubMed     Abstract available
    
    
    January 2020
28. YANG Y, Wei Q, Tang Y, Yuanyuan Wang, et al
    Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30043.
    PubMed     Abstract available
    
    
    
29. WANG Y
    Comment on "Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer," Cancer Lett. 2020 Jan 2; 473 (2020) 139-147.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30045.
    PubMed    
    
    
    
30. NAN X, Wang J, Cheng H, Yin Z, et al
    Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer Lett. 2020;469:195-206.
    PubMed     Abstract available
    
    
    
31. SHENG R, Li X, Wang Z, Wang X, et al
    Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30665.
    PubMed     Abstract available
    
    
    
32. ZHANG Y, Li X, Zhang J, Liang H, et al
    Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30660.
    PubMed     Abstract available
    
    
    December 2019
33. LIU W, Wang W, Wang X, Xu C, et al
    Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
    Cancer Lett. 2019;472:59-69.
    PubMed     Abstract available
    
    
    
34. WANG R, Pan W, Jin L, Huang W, et al
    Human papillomavirus vaccine against cervical cancer: opportunity and challenge.
    Cancer Lett. 2019 Dec 5. pii: S0304-3835(19)30604.
    PubMed     Abstract available
    
    
    
35. KASHYAP VK, Dan N, Chauhan N, Wang Q, et al
    VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.
    Cancer Lett. 2019 Dec 3. pii: S0304-3835(19)30590.
    PubMed     Abstract available
    
    
    November 2019
36. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett 415 (20-29)].
    Cancer Lett. 2019 Nov 15. pii: S0304-3835(19)30561.
    PubMed    
    
    
    
37. WU H, Song S, Yan A, Guo X, et al
    RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1.
    Cancer Lett. 2019 Nov 6. pii: S0304-3835(19)30557.
    PubMed     Abstract available
    
    
    October 2019
38. ALI R, Alabdullah M, Alblihy A, Miligy I, et al
    PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Cancer Lett. 2019 Oct 24. pii: S0304-3835(19)30538.
    PubMed     Abstract available
    
    
    
39. GAO T, Zhang X, Zhao J, Zhou F, et al
    SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1alpha pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Cancer Lett. 2019 Oct 19. pii: S0304-3835(19)30526.
    PubMed     Abstract available
    
    
    
40. ZHANG Z, Zhang L, Wang B, Wei R, et al
    MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
    Cancer Lett. 2019 Oct 17. pii: S0304-3835(19)30518.
    PubMed     Abstract available
    
    
    
41. ASANTE DB, Calapre L, Ziman M, Meniawy TM, et al
    Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
    Cancer Lett. 2019 Oct 11. pii: S0304-3835(19)30511.
    PubMed     Abstract available
    
    
    September 2019
42. FENG S, Liu W, Bai X, Pan W, et al
    LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer.
    Cancer Lett. 2019;465:105-117.
    PubMed     Abstract available
    
    
    July 2019
43. CAUMANNS JJ, van Wijngaarden A, Kol A, Meersma GJ, et al
    Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer Lett. 2019 Jul 15. pii: S0304-3835(19)30400.
    PubMed     Abstract available
    
    
    
44. PARAYATH NN, Gandham SK, Leslie F, Amiji MM, et al
    Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
    Cancer Lett. 2019;461:1-9.
    PubMed     Abstract available
    
    
    June 2019
45. CHEN J, Deng Y, Ao L, Song Y, et al
    The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF-beta/Smad pathway in cervical cancer.
    Cancer Lett. 2019 Jun 24. pii: S0304-3835(19)30376.
    PubMed     Abstract available
    
    
    
46. ZHANG M, Jabbari N, Satpathy M, Matyunina LV, et al
    Sequence diverse miRNAs converge to induce mesenchymal-to-epithelial transition in ovarian cancer cells through direct and indirect regulatory controls.
    Cancer Lett. 2019 Jun 1. pii: S0304-3835(19)30340.
    PubMed     Abstract available
    
    
    May 2019
47. KREUZINGER C, von der Decken I, Wolf A, Gamperl M, et al
    Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Cancer Lett. 2019;459:1-12.
    PubMed     Abstract available
    
    
    
48. SU PH, Hsu YW, Huang RL, Chen LY, et al
    TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions.
    Cancer Lett. 2019;450:53-62.
    PubMed     Abstract available
    
    
    
49. FOGG KC, Olson WR, Miller JN, Khan A, et al
    Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.
    Cancer Lett. 2019 May 23. pii: S0304-3835(19)30324.
    PubMed     Abstract available
    
    
    March 2019
50. HAN W, Zhang Y, Niu C, Guo J, et al
    BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
    Cancer Lett. 2019;445:45-56.
    PubMed     Abstract available
    
    
    
51. CHE Y, Li Y, Zheng F, Zou K, et al
    TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
    Cancer Lett. 2019;452:1-13.
    PubMed     Abstract available
    
    
    February 2019
52. VLIET-GREGG PA, Robinson KL, Levan J, Matsumoto LR, et al
    NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells.
    Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30102.
    PubMed     Abstract available
    
    
    
53. ZHAO H, Jin L, Li Y, Zhang C, et al
    Oncofertility: What can we do from bench to bedside?
    Cancer Lett. 2019;442:148-160.
    PubMed     Abstract available
    
    
    November 2018
54. RADHAKRISHNAN R, Ha JH, Jayaraman M, Liu J, et al
    Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30689.
    PubMed     Abstract available
    
    
    October 2018
55. LV Q, Xie L, Cheng Y, Shi Y, et al
    A20-mediated deubiquitination of ERalpha in the microenvironment of CD163(+) macrophages sensitizes endometrial cancer cells to estrogen.
    Cancer Lett. 2018;442:137-147.
    PubMed     Abstract available
    
    
    
56. PENG Y, Kajiyama H, Yuan H, Nakamura K, et al
    PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Cancer Lett. 2018;442:181-192.
    PubMed     Abstract available
    
    
    September 2018
57. YANG P, Su C, Luo X, Zeng H, et al
    Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway.
    Cancer Lett. 2018 Sep 10. pii: S0304-3835(18)30559.
    PubMed     Abstract available
    
    
    August 2018
58. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett. 2018 Feb 28; 415:20-29].
    Cancer Lett. 2018 Aug 18. pii: S0304-3835(18)30502.
    PubMed    
    
    
    
59. KREITZBURG KM, Fehling SC, Landen CN, Gamblin TL, et al
    FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Cancer Lett. 2018 Aug 15. pii: S0304-3835(18)30527.
    PubMed     Abstract available
    
    
    
60. CHEN X, Zhou J, Li X, Wang X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.
    Cancer Lett. 2018;435:80-91.
    PubMed     Abstract available
    
    
    July 2018
61. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Abstract available
    
    
    June 2018
62. MALDONADO L, Brait M, Izumchenko E, Begum S, et al
    Integrated Transcriptomic and Epigenomic Analysis of Ovarian Cancer Reveals Epigenetically Silenced GULP1.
    Cancer Lett. 2018 Jun 28. pii: S0304-3835(18)30436.
    PubMed     Abstract available
    
    
    
63. ZHANG Q, Li Y, Miao C, Wang Y, et al
    Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.
    Cancer Lett. 2018 Jun 4. pii: S0304-3835(18)30390.
    PubMed     Abstract available
    
    
    April 2018
64. MENG Y, Chen CW, Yung MMH, Sun W, et al
    DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30296.
    PubMed     Abstract available
    
    
    
65. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Abstract available
    
    
    March 2018
66. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Abstract available
    
    
    
67. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Abstract available
    
    
    February 2018
68. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Abstract available
    
    
    
69. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Abstract available
    
    
    January 2018
70. GUO J, Yang Z, Yang X, Li T, et al
    miR-346 functions as a pro-survival factor under ER stress by activating mitophagy.
    Cancer Lett. 2018;413:69-81.
    PubMed     Abstract available
    
    
    December 2017
71. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Abstract available
    
    
    November 2017
72. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Abstract available
    
    
    October 2017
73. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Abstract available
    
    
    
74. WANG J, Man GCW, Chan TH, Kwong J, et al
    A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30623.
    PubMed     Abstract available
    
    
    
75. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Abstract available
    
    
    
76. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Abstract available
    
    
    September 2017
77. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: